Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Receivables: 2017-2025

Historic Receivables for Aclaris Therapeutics (ACRS) over the last 7 years, with Jun 2025 value amounting to $194,000.

  • Aclaris Therapeutics' Receivables fell 72.29% to $194,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $1.1 million, marking a year-over-year decrease of 35.64%. This contributed to the annual value of $318,000 for FY2024, which is 6.71% up from last year.
  • As of Q2 2025, Aclaris Therapeutics' Receivables stood at $194,000, which was down 22.40% from $250,000 recorded in Q1 2025.
  • Aclaris Therapeutics' 5-year Receivables high stood at $963,000 for Q2 2021, and its period low was $194,000 during Q2 2025.
  • In the last 3 years, Aclaris Therapeutics' Receivables had a median value of $344,500 in 2023 and averaged $393,900.
  • In the last 5 years, Aclaris Therapeutics' Receivables soared by 62.41% in 2024 and then slumped by 72.29% in 2025.
  • Aclaris Therapeutics' Receivables (Quarterly) stood at $647,000 in 2021, then declined by 25.19% to $484,000 in 2022, then crashed by 38.43% to $298,000 in 2023, then increased by 6.71% to $318,000 in 2024, then tumbled by 72.29% to $194,000 in 2025.
  • Its Receivables was $194,000 in Q2 2025, compared to $250,000 in Q1 2025 and $318,000 in Q4 2024.